Oryzon Genomics 관리

관리 기준 확인 2/4

Oryzon Genomics CEO는 Carlos Manuel Arjol, Jan2000 에 임명되었습니다 의 임기는 24.83 년입니다. 총 연간 보상은 $ 503.42K, 68.6% 로 구성됩니다. 68.6% 급여 및 31.4% 보너스(회사 주식 및 옵션 포함). 는 € 4.52M 가치에 해당하는 회사 주식의 4.61% 직접 소유합니다. 4.52M. 경영진과 이사회의 평균 재임 기간은 각각 5.1 년과 9 년입니다.

주요 정보

Carlos Manuel Arjol

최고 경영자

US$503.4k

총 보상

CEO 급여 비율	68.6%
CEO 임기	24.8yrs
CEO 소유권	4.6%
경영진 평균 재임 기간	5.1yrs
이사회 평균 재임 기간	9yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Carlos Manuel Arjol 의 보수는 Oryzon Genomics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$5m
Jun 30 2024	n/a	n/a	-US$4m
Mar 31 2024	n/a	n/a	-US$3m
Dec 31 2023	US$503k	US$346k	-US$4m
Sep 30 2023	n/a	n/a	-US$4m
Jun 30 2023	n/a	n/a	-US$4m
Mar 31 2023	n/a	n/a	-US$5m
Dec 31 2022	US$451k	n/a	-US$5m

보상 대 시장: Carlos Manuel 의 총 보상 ($USD 503.42K )은 UK 시장( $USD 354.22K ).

보상과 수익: 회사가 수익성이 없는 동안 Carlos Manuel 의 보상이 증가했습니다.

CEO

Carlos Manuel Arjol

24.8yrs

테뉴어

US$503,422

보상

Dr. Carlos Manuel Buesa Arjol Co-Founded Oryzon Genomics S.A. in 2000 and has been its Chairman and Chief Executive Officer since 2001 and serves as its President and served as its Member of Financial Advi...

리더십 팀

이름	위치	테뉴어	보상	소유권
Carlos Manuel Arjol	Co-Founder	24.8yrs	US$503.42k	4.61% € 4.5m
Enric Condomines	COO & CFO	4.4yrs	데이터 없음	데이터 없음
Jordi Pey	Scientific Director	3.8yrs	데이터 없음	데이터 없음
Xavier Ribera	Head of Internal Audit & Compliance	no data	데이터 없음	데이터 없음
Augusto Rubio	Secretary	no data	데이터 없음	데이터 없음
Emili Cortada	Director of Business Development	no data	데이터 없음	데이터 없음
Neus Bernado	Director of Industrial Property	no data	데이터 없음	데이터 없음
Michael Ropacki	Medical Director of SNC	5.8yrs	데이터 없음	데이터 없음
Sonia Paloma Bezon	Director of Clinical Operations	no data	데이터 없음	데이터 없음

5.1yrs

평균 재임 기간

경험이 풍부한 관리: 0RDB 의 관리팀은 노련하고 경험 (평균 재직 기간 5.1 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Carlos Manuel Arjol	Co-Founder	23.8yrs	US$503.42k	4.61% € 4.5m
Howard Fillit	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Isabel Aguilera Navarro	Independent Director	9yrs	US$49.68k	데이터 없음
Lori Kunkel	Member of Scientific Advisory Board	6.8yrs	데이터 없음	데이터 없음
Manuel López-Figueroa	Lead Independent Director	4.5yrs	US$72.86k	데이터 없음
Josep Echarri Torres	Director	22.8yrs	US$29.81k	1.98% € 1.9m
Tamara Maes	VP of the Board & President of Scientific Advisory Board	24.8yrs	US$41.95k	3.96% € 3.9m
Ramon Ramon	Independent Director	9yrs	US$54.10k	0.029% € 28.6k
Leon Hooftman	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Antonio Melero	Independent Director	9yrs	US$54.10k	데이터 없음
Felipe Cardoso	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Jose Molinuevo	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음

9.0yrs

평균 재임 기간

66yo

평균 연령

경험이 풍부한 이사회: 0RDB 의 이사회는 경험(평균 재직 기간 9 년)으로 간주됩니다.

Oryzon Genomics 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Insufficient new directors

Oryzon Genomics S.A. Announces Appointment of Douglas V. Faller as Global Chief Medical Officer

Oryzon Genomics S.A. Announces Executive Changes

Recent updates

Forecast to breakeven in 2025

No longer forecast to breakeven

No longer forecast to breakeven

Forecast to breakeven in 2025

New minor risk - Shareholder dilution

No longer forecast to breakeven

Oryzon Genomics, S.A. Announces Presentation of Final Data from Portico, Vafidemstat's Global Phase IIb Trial in Borderline Personal Disorder, at the 37th ECNP Annual Conference

Oryzon Genomics S.A. Presents Preliminary Data from Ongoing Phase Ib Frida Trial with Iadademstat Plus Gilteritinib in Relapsed/Refractory Flt3-Mut Aml Patients At Eha-2024

Forecast breakeven date moved forward to 2025

Oryzon Genomics, S.A. Secures Another Important Patent for its Lead CNS Asset, Vafidemstat

Forecast breakeven date pushed back to 2026

New minor risk - Share price stability

ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer

New major risk - Revenue and earnings growth

New minor risk - Profitability

Forecast to breakeven in 2025

Oryzon Genomics, S.A. Announces Topline Results from Phase IIb Portico Study of Vafidemstat in Borderline Personality Disorder

New major risk - Financial position

Oryzon Genomics S.A. announced that it expects to receive €45 million in funding from Nice & Green SA

Oryzon Genomics, S.A. Announces Last Patient Last Visit in Its Phase IIb Portico Study for Borderline Personality Disorder

Oryzon Genomics, S.A. Presents Blinded Aggregated Safety Data from Vafidemstat's Ongoing Phase IIB Portico Trial in Borderline Personal Disorder

New major risk - Financial position

Oryzon Genomics, S.A. Reports New Preliminary Blinded Aggregate Safety Data from Its Ongoing Phase IIb Portico Trial

Oryzon Genomics, S.A. Presents Positive Preclinical Data of Ory-4001 for the Treatment of Charcot-Marie-Tooth Disease Presented At the 2023 Peripheral Nerve Society Annual Meeting

Insufficient new directors

Oryzon Genomics, S.A. to Present Positive Preclinical Efficacy Data of ORY-4001 in Charcot-Marie-Tooth (CMT) Disease At the 2023 Peripheral Nerve Society Annual Meeting

Forecast to breakeven in 2025

Oryzon Genomics S.A. announced that it has received €1.800407 million in funding

ORYZON Announces FDA Clearance of IND to Initiate a Collaborative Phase II Basket Study with Iadademstat in R/R Patients with Neuroendocrine Carcinomas (NECs)

Oryzon Genomics S.A. announced that it expects to receive €20 million in funding from Nice & Green SA

Oryzon Genomics S.A. At Eha-2022: Iadademstat 42-Month Alice Data Demonstrate Robust Efficacy in Combination with Azacitidine in AML

Oryzon Starts Preclinical Collaboration on Kabuki Syndrome with Kennedy Krieger Institute and Johns Hopkins University

Oryzon Genomics S.A. Announces Appointment of Douglas V. Faller as Global Chief Medical Officer

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

ORYZON Announces Approval for Serbian Arm of PORTICO, Vafidemstat’s Phase IIb Trial in Borderline Personality Disorder

Oryzon Genomics S.A. Presents Iadademstat 36-Month Alice Data Demonstrate Robust Efficacy in Combination with Azacitidine in AML

Oryzon Announces $1 Million Grant from Kabuki Syndrome Philanthropists to Support A Precision Medicine Phase I/Ii Trial with Vafidemstat

First half 2021 earnings released: €0.019 loss per share (vs €0.026 loss in 1H 2020)

Oryzon Genomics S.A. Receives Approval to Start EVOLUTION Phase IIb trial with vafidemstat in schizophrenia

Oryzon Genomics, S.A. Announces FDA Approval of IND for Portico, Phase IIb Trial with Vafidemstat in Borderline Personality Disorder

ORYZON Presents Iadademstat ALICE 30-Month Data at EHA-2021, Confirming Positive and Robust Efficacy in Combination with Azacitidine in AML

ORYZON to Present New Clinical Data

Oryzon Genomics, S.A. Announces Successful pre-IND Meeting with FDA for the Clinical Development of vafidemstatin Borderline Personality Disorder

Oryzon Genomics S.A. Presents Vafidemstat 12-Month Clinical Data from Its Phase IIa Clinical Trials

Full year 2020 earnings released

New 90-day high: €3.84

Oryzon Genomics S.A. Launches Pioneering Schizophrenia Precision Medicine Study in Collaboration with Columbia Psychiatry

New 90-day high: €3.18

New 90-day low: €2.69

Oryzon Genomics S.A. to Present Further Positive Efficacy Data From Iadademstat ALICE Phase IIa Trial at the 62nd Congress of the American Society of Hematology

Oryzon Genomics, S.A. Receives Approval to Start PORTICO Phase IIb Trial with Vafidemstat in Borderline Personality Disorder

Oryzon Genomics S.A. Announces Executive Changes

Third quarter earnings released

New 90-day low: €2.71

Oryzon Genomics S.A. has completed a Follow-on Equity Offering in the amount of €20.00075 million.

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간

평균 연령